以mRNA技术培育生物医药产业新质生产力的实证分析——以浙江省为例

An Empirical Analysis of Cultivating New Quality Productivity of Biomedical Industry with mRNA Technology —— Taking Zhejiang Province as an Example

关键词:  mRNA  生物医药产业  新质生产力  实证分析  浙江省

Key words:  mRNA  biomedical industry  new quality productivity  empirical analysis  zhejiang province

摘要:

目的 探讨浙江省如何利用mRNA技术培育生物医药产业新质生产力,提升产业竞争力,缩小与全球领先地区的差距。方法 通过文献调研、专利分析和实地考察,综合评估浙江省在mRNA领域的科研实力、创新平台、产业化基础,并识别其在技术壁垒、资金短缺、产业链协同不足和监管审批滞后等方面面临的主要挑战。结果 浙江省在mRNA研究和产业化方面已具备一定基础,但与国际先进水平相比,仍存在关键技术储备不足、融资难度大、产业链协同性弱和监管审批效率低等问题。提出的对策包括加强关键技术研发、优化资金和人才资源配置、促进产学研医深度合作和完善政策环境。结论 浙江省需通过强化mRNA技术攻关、提升资源配置效率、深化产业合作和优化政策支持,以加速mRNA技术在生物医药产业的转化应用,培育产业新动能,提升整体竞争力,形成具有全球影响力的生物医药产业新质生产力。

Abstract:

OBJECTIVE To explore how Zhejiang Province can cultivate new quality productivity in the biomedical industry using mRNA technology, enhance industrial competitiveness, and narrow the gap with the leading regions worldwide. METHODS Through literature research, patent analysis, and on-the-spot investigation, we comprehensively evaluated the scientific research strength, innovation platform, and industrialization foundation in the mRNA field in Zhejiang Province. We identified the main challenges regarding technical barriers, shortage of funds, insufficient industrial chain coordination, and lagging regulatory approval. RESULTS Zhejiang province has a certain degree of foundation in mRNA research and industrialization. However, compared with the advanced international peers, there are still some problems, such as insufficient key technology reserves, complex financing, weak industrial chain coordination, and low efficiency of supervision and approval. The countermeasures include strengthening the research and development of critical technologies, optimizing the allocation of funds and human resources, promoting in-depth cooperation between industry and academy research, and improving the policy environment. CONCLUSION Zhejiang Province needs to strengthen mRNA technology to tackle fundamental research problems, improve the efficiency of resource allocation, deepen industrial cooperation, and optimize policy support to accelerate the transformation and application of mRNA technology, cultivate new industrial kinetic energy, enhance overall competitiveness, and form new quality productivity of biomedical industry with global influence.